October 22, 2020

Angiotensin Enzyme Inhibitors and Angiotensin Receptor Blockers as Protective Factors in COVID-19 Mortality: A Retrospective Cohort Study

Category: Article Summary

Topic: Testing and Treatment

Keywords (Tags): clinical characteristics

• Odds of mortality were reduced in half among participants taking angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (95% CI = 0.3-0.7) in a retrospective cohort study (n=2,553) after adjusting for underlying conditions, length of stay, age, gender, and ICU admission. A notable confounder was the higher mortality frequency in patients with a history of underlying disease (22.4% vs 12.7%).

Yahyavi et al. (Oct 21, 2020). Angiotensin Enzyme Inhibitors and Angiotensin Receptor Blockers as Protective Factors in COVID-19 Mortality: A Retrospective Cohort Study. Internal and Emergency Medicine. https://doi.org/10.1007/s11739-020-02523-9